The prevalence of psoriasis in the world

Raychaudhuri, Siba P; Farber, Eugene M.

doi:10.1046/j.1468-3083.2001.00192.x

Cited by 270 publications

(244 citation statements)

References 6 publications

(10 reference statements)

Supporting

Mentioning

224

Contrasting

Unclassified

Order By: Relevance

“…The occurrence of PsA has been estimated at between 6% and 42% of patients afflicted with psoriasis [2][3][4][5][6], which occurs in 1-3% of the population [7][8][9]. The clinical manifestations of PsA include arthritis, enthesitis, dactylitis, spondylitis, psoriasis, and nail disease, with approximately 50% of patients also experiencing erosive joint damage within the first 2 years [10].…”

Section: Introductionmentioning

confidence: 99%

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Mease

McInnes

2016

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Mease

McInnes

2016

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

“…It is a life long chronic inflammatory condition affecting approximately 2% of general population. 1 The etiology is still unknown, while genetic, metabolic and immunological mechanism has been implicated. Psoriasis has been associated with an increased morbidity and mortality from high frequency of cardiovascular events.…”

Section: Introductionmentioning

confidence: 99%

Dyslipidemia in psoriasis: as a risk for cardiovascular disease

Dsouza

Kuruville

2013

Int J Res Med Sci

View full text Add to dashboard Cite

INTRODUCTIONPsoriasis is a common chronic recurrent inflammatory skin disorder characterized by hyperproliferation and reduced differentiation of keratinocytes. It is a life long chronic inflammatory condition affecting approximately 2% of general population.1 The etiology is still unknown, while genetic, metabolic and immunological mechanism has been implicated. Psoriasis has been associated with an increased morbidity and mortality from high frequency of cardiovascular events. This seems to be related to the severity of psoriasis, considering that it occurs much more frequently in patients presenting with large areas of body affected with psoriatic lesions. However, the pathogenesis of atherothrombotic events in psoriasis patients remains to be recognized. Multiple factors including abnormal lipids and lipoprotein profiles and risk factors such as hypertension, obesity, diabetes mellitus have been associated with psoriasis.3 Several reports suggests that psoriatic patients have proatherogenic lipid profile including increased levels of serum triglycerides, LDL-cholesterol, VLDL-cholesterol and low HDL-cholesterol levels. However, studies are ABSTRACT Background: Psoriasis is a common and recurrent proliferative inflammatory skin disease that has been associated with abnormal plasma lipid metabolism and with high frequency of cardiovascular morbidity and mortality. The prevalence seems to be related to the severity of psoriasis, as it occurs more frequently in patients presenting with large areas of the body affected with lesions. The aim of our work was to evaluate the development of dyslipidemia in psoriasis, and to look for a correlation between their levels and severity of diseases in which the risk factors and secondary causes of hyperlipidemia were excluded. Methods: We evaluated the fasting lipid profile in twenty-four patients with mild to moderate psoriasis and twentyfour age and gender matched healthy subjects as the control group. Results: Patients presented risk changes in lipid profile, serum total cholesterol (p<0.001), triglyceride (p<0.01), LDL-cholesterol (p<0.001), VLDL-cholesterol (p<0.01) and TC/HDL ratio (p<0.01) were found to be significantly higher than in control group. No significant statistical difference was observed between HDL levels of the two groups. Significant positive correlation in total cholesterol and LDL-cholesterol was found between mild and moderate psoriasis (PASI score) as compared with controls. Conclusion: Our data suggest that psoriasis patients must be considered as a group at high risk for cardiovascular, since psoriasis per se seems to be associated with risk changes in the lipid profile. We conclude that psoriatic patients should be evaluated and followed up for the risk of hyperlipidemia and cardiovascular diseases.

show abstract

“…Psoriasis is the most common autoimmune disease in the United States and affects about 2% of the population (Gelfand et al, 2005;Langley, Kreuger, & Griffiths, 2005;Raychaudhuri & Farber, 2001). It causes red flaky patches on the skin, known as scales.…”

Section: Introductionmentioning

confidence: 99%

There Is Hope: Autogenic Biofeedback Training for the Treatment of Psoriasis

Klein

Peper

2013

Biofeedback

View full text Add to dashboard Cite

Many college students experience stress-related illness, and in one study, 82% of students reported significant improvement in health when they participated in a semester-long stress management program. The factors that contribute to symptom reduction are illustrated by the case report of a 23-year-old male student who had been suffering from psoriasis for the past 5 years, which was not alleviated with medication and traditional medical treatment. He participated in an integrated selfregulation program consisting of daily self-healing home practice for 3 weeks, a desensitization strategy, autogenic training, and biofeedback training, coupled with pre-and posttreatment biofeedback assessments. Results showed a significant improvement in the clearing of the skin, more positive self-talk, and improved posture. The benefits have been maintained at the 4-month follow-up. Discussed are the training components and procedures along with factors that contributed to the clinical success and that can be applied to numerous other stress-related disorders.

show abstract

The prevalence of psoriasis in the world

Cited by 270 publications

References 6 publications

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Dyslipidemia in psoriasis: as a risk for cardiovascular disease

There Is Hope: Autogenic Biofeedback Training for the Treatment of Psoriasis

Contact Info

Product

Resources

About